Canada Spends Logo

Explore our Budget 2026 analysis

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

University of Calgary

$120,000.00

The role of the subjective experience in supporting positive effects following psilocybin: a randomized, controlled clinical trial using risperidone in healthy adults

FY 2025-26

Summary
Recent research suggests that psychedelics such as psilocybin, the active compound in "magic mushrooms," may be effective in treating a range of mental health conditions and improving well-being and mood. However, the biological mechanisms behind these effects are not clear. The subjective effects of psilocybin, mediated through its activation of serotonin 2A receptors, have been linked to lasting therapeutic effects in some clinical trials, but not in others. It is therefore unclear whether the subjective experience is necessary for psilocybin's lasting effects on outcomes such as well-being and mood. Drugs that block activation of serotonin 2A receptors, such as risperidone, diminish or completely erase the psychedelic experience when taken together with psilocybin and can be used to test the importance of these subjective effects. This study will test whether blocking the serotonin-mediated psychedelic experience (via risperidone) alters the acute biological response to psilocybin and its long-term effects. To determine this, 100 healthy adults will be given either a low or a high dose of psilocybin, in combination with either risperidone or placebo. Participants' acute response to psilocybin will be monitored during the drug session to explore the relationship between subjective effects and biological responses, with a particular focus on cortisol, the body's main stress hormone. Participants will complete measures of well-being and mood before and after the drug session. The difference in these measures between participants who receive psilocybin with risperidone and those who receive psilocybin alone will be compared to assess the impact of the subjective experience. The results of this project will provide the first evidence as to whether the subjective effects of psilocybin are necessary for its long-term effects on mood and well-being in healthy people.
Program
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
559814
Name
Deutsch Ana
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
The role of the subjective experience in supporting positive effects following psilocybin: a randomized, controlled clinical trial using risperidone in healthy adults
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Cortisol; Healthy Participants; Mood; Psilocybin; Psychedelics; Stress; Subjective Effects; Well-Being
Abstract
Recent research suggests that psychedelics such as psilocybin, the active compound in "magic mushrooms," may be effective in treating a range of mental health conditions and improving well-being and mood. However, the biological mechanisms behind these effects are not clear. The subjective effects of psilocybin, mediated through its activation of serotonin 2A receptors, have been linked to lasting therapeutic effects in some clinical trials, but not in others. It is therefore unclear whether the subjective experience is necessary for psilocybin's lasting effects on outcomes such as well-being and mood. Drugs that block activation of serotonin 2A receptors, such as risperidone, diminish or completely erase the psychedelic experience when taken together with psilocybin and can be used to test the importance of these subjective effects. This study will test whether blocking the serotonin-mediated psychedelic experience (via risperidone) alters the acute biological response to psilocybin and its long-term effects. To determine this, 100 healthy adults will be given either a low or a high dose of psilocybin, in combination with either risperidone or placebo. Participants' acute response to psilocybin will be monitored during the drug session to explore the relationship between subjective effects and biological responses, with a particular focus on cortisol, the body's main stress hormone. Participants will complete measures of well-being and mood before and after the drug session. The difference in these measures between participants who receive psilocybin with risperidone and those who receive psilocybin alone will be compared to assess the impact of the subjective experience. The results of this project will provide the first evidence as to whether the subjective effects of psilocybin are necessary for its long-term effects on mood and well-being in healthy people.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Deutsch, Ana
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~
University of Calgary - $120,000 Grant (2025-26) | Canada Spends